Dr. Joris Schuller, M.D.
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 376
Licensed in Texas since 1997, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: University of Texas Southwestern Medical School at Dallas
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
TX license K2119 (first issued 1997; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baylor University Medical Center Dallas, TX
- Baylor Scott & White Medical Center Grapevine Grapevine, TX
- Baylor Scott & White Heart & Vascular Hospital - Dallas Dallas, TX
Medical groups
- Dallas Nephrology Associates (157 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 376
- Services billed
- 3,485
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 478 | 138 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 311 | 121 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 235 | 35 |
| Established patient office or other outpatient visit, 40-54 minutes | 161 | 106 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 95 | 89 |
| Established patient office or other outpatient visit, 30-39 minutes | 68 | 60 |
| Hemodialysis procedure with physician evaluation | 41 | 24 |
| Critical care, first 30-74 minutes | 40 | 21 |
| New patient office or other outpatient visit, 60-74 minutes | 31 | 31 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 17 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carvedilol Other prescribers in Dallas, TX | 98 |
| Sevelamer Carbonate Other prescribers in Dallas, TX | 78 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Dallas, TX | 73 |
| Nifedipine Er (nifedipine) Other prescribers in Dallas, TX | 72 |
| Amlodipine Besylate Other prescribers in Dallas, TX | 70 |
| Chlorthalidone Other prescribers in Dallas, TX | 67 |
| Losartan Potassium Other prescribers in Dallas, TX | 65 |
| Torsemide Other prescribers in Dallas, TX | 59 |
| Calcium Acetate Other prescribers in Dallas, TX | 47 |
| Calcitriol Other prescribers in Dallas, TX | 45 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 36 payments worth $696 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $157 |
|---|---|
| Alexion Pharmaceuticals, Inc. | $95.72 |
| Amgen Inc. | $75.81 |
| Veloxis Pharmaceuticals, Inc. | $62.58 |
| Otsuka America Pharmaceutical, Inc. | $47.22 |
| Nxstage Medical, Inc. | $38.98 |
| Calliditas Therapeutics US Inc. | $33.69 |
| Apellis Pharmaceuticals, Inc. | $32.84 |
| Food and Beverage | $694 |
|---|---|
| Education | $2.05 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Travere Therapeutics, Inc. Oct 14, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Dec 4, 2025 | Education Filspari · Kidney Disease · in-kind | $0.39 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.